India’s Pharma for the World
Trust travels far. Indian medicines today reach over 200 countries — trusted in remote rural clinics and deployed in humanitarian health crises around the world. As the #1 exporter of vaccines globally and the third-largest pharmaceutical producer by volume, India plays a decisive role in global public health. With $30.5 billion in pharmaceutical exports in FY24 and a dominant share in generics to markets like the US and UK, India’s pharmaceutical sector is both vast and vital.
For over 25 years, IPA has supported this global leadership — facilitating bilateral agreements, engaging with regulators and trade bodies, and strengthening India’s reputation for high-quality, affordable, and resilient pharmaceutical supply.
200+ Countries Served
With 30+ countries reliant on Indian APIs & finished drugs
#1 in Vaccines
Over 60% of global vaccines are Indian-made
$30.5 B in Exports
FY 2024–25 pharma exports — up 9.4% YoY
Global Reach: Expanding Access, Shaping Policy
From trade negotiations to regulatory alignment, IPA champions India’s pharmaceutical leadership on the world stage — driving access, trust, and collaboration across borders.
Public Health at the Core of TRIPS
A legacy of advocacy for balanced IP rights.
From Section 3(d) to global TRIPS negotiations, IPA champions policies that support innovation without monopoly, ensuring affordable access to medicines remains protected.
Learn more: TRIPS and Public Health SafeguardsGlobal Generics & Biosimilar Leadership
Driving the future through the IGBA.
IPA holds leadership roles in the International Generic and Biosimilar Medicines Association, shaping global discussions through the CEO Advisory and Management Committees. Highlights include the Global Generics Vision Report and contributions to USTR-301 and market access dialogue.
Read: Global Generics & Biosimilars Vision 2030
Global Partnerships
India–US Medicines Partnership
IPA is a key force behind the US–India Affordable Medicines Partnership.
Through CEO-led delegations and engagement with the US FDA, IPA works to build regulatory trust, promote affordability, and strengthen medicine supply chains between the two nations.
Read: De-risking the US Supply ChainBilateral & Multilateral Trade Engagement
Shaping India's global trade narrative.
IPA supports India’s pharmaceutical trade diplomacy with partners, including Australia, the UAE, EFTA, the EU, and the UK, advocating for frameworks that balance market access and public health priorities.
Explore India’s Pharma Trade Partnerships
Research, Reports & Policy Impact
Evidence-led advocacy for global trust.
Reflecting IPA’s commitment to transparency, data integrity, and thought leadership, IPA publishes strategic insights on key international issues, including:
- De-risking the U.S. Supply Chain
- Market Access Barriers
- USTR-301 Policy Submissions
The World Is Changing — So Is Indian Pharma.
Today’s healthcare and trade ecosystems are being reshaped — and India must lead from the front.
Blockbuster Opportunities
With 55+ blockbuster drugs going off-patent by 2030, India has a unique opportunity to deliver high-quality, affordable alternatives. IPA’s vision report outlines the strategy for global leadership.
Read: Global Generics & Biosimilars ReportThe World’s Pharmacy, The World’s Partner
Explore More Impact Stories
HIV Drugs at 1/100th the Cost
Indian generics helped Brazil reduce HIV treatment costs dramatically — enabling the government to expand coverage for vulnerable populations.
Fighting Malaria with the Global Fund
IPA members have supplied high-quality ACTs and diagnostics across Sub-Saharan Africa under WHO-led and Global Fund campaigns.
Emergency Supply During Crisis
In 2022, Indian pharmaceutical firms were among the first to supply essential medicines and humanitarian kits during the Ukrainian conflict.